Vascepa (icosapent ethyl)

About Ligand Pharmaceuticals

Ligand Pharmaceuticals operates a unique, asset-light business model focused on acquiring and licensing royalty rights to pharmaceutical assets and technologies, which it partners with other companies for development and commercialization. Its core achievement is building a diversified, revenue-generating portfolio from blockbuster drugs like Promacta®, Kyprolis®, and Veklury®, underpinned by its proprietary Captisol® drug formulation platform. This strategy provides predictable, high-margin royalty streams while minimizing direct exposure to clinical trial risk and commercial infrastructure costs. The company's mission is to act as a financier and enabler within the biopharma ecosystem, leveraging its scientific and financial expertise to share in the success of innovative therapies.

Therapeutic Areas

Other Cardiovascular Risk Reduction Drugs